Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord Injury - A Multicenter International Randomized Double Blind Placebo Controlled Phase II Clinical Proof of Concept Trial
Latest Information Update: 27 Oct 2023
At a glance
- Drugs ATI 355 (Primary)
- Indications Spinal cord injuries
- Focus Proof of concept; Therapeutic Use
- Acronyms NISCI
Most Recent Events
- 03 Apr 2023 Status changed from active, no longer recruiting to completed.
- 22 Jan 2023 This trial has been completed in Czech Republic according to European Clinical Trials Database record.
- 24 Aug 2022 Planned primary completion date changed from 30 Dec 2022 to 28 Feb 2023.